Abstract
The human genome encodes thousands of natural antisense long noncoding RNAs (lncRNAs); they play the essential role in regulation of gene expression at multiple levels, including replication, transcription and translation. Dysregulation of antisense lncRNAs plays indispensable roles in numerous biological progress, such as tumour progression, metastasis and resistance to therapeutic agents. To date, there have been several studies analysing antisense lncRNAs expression profiles in cancer, but not enough to highlight the complexity of the disease. In this study, we investigated the expression patterns of antisense lncRNAs from osteosarcoma and healthy bone samples (24 tumour-16 bone samples) using RNA sequencing. We identified 15 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, PTOV1-AS1, UBE2D3-AS1, ERCC8-AS1, ZMIZ1-AS1, RNF144A-AS1, RDH10-AS1, TRG-AS1, GSN-AS1, HMGA2-AS1, ZNF528-AS1, OTUD6B-AS1, COX10-AS1 and SLC16A1-AS1) that were upregulated in tumour samples compared to bone sample controls. Further, we performed real-time polymerase chain reaction (RT-qPCR) to validate the expressions of the antisense lncRNAs in 8 different osteosarcoma cell lines (SaOS-2, G-292, HOS, U2-OS, 143B, SJSA-1, MG-63, and MNNG/HOS) compared to hFOB (human osteoblast cell line). These differentially expressed IncRNAs can be considered biomarkers and potential therapeutic targets for osteosarcoma.
Highlights
Osteosarcoma (OS), known as osteogenic sarcoma, is the most common primary malignant solid tumour of bone [1]
The results showed that 15 antisense long noncoding RNAs (lncRNAs)
The results have shown that only 7 antisense lncRNAs (RUSC1-AS1, TBX2-AS1, UBE2D3-AS1, ERCC8AS1, HMGA2-AS1, OTUD6B-AS1, and COX10-AS1) have validation of transcript expression by Real Time-Quantitative Polymerase Chain Reaction (RT-qPCR) (Figure 5)
Summary
Osteosarcoma (OS), known as osteogenic sarcoma, is the most common primary malignant solid tumour of bone [1]. OS commonly develops in the extremities of long bones such as the distal femur, proximal tibia, proximal humerus, and proximal femur [3]. It is an aggressive-invasion sarcoma type that frequently metastasizes to the lung and other bones in the body [4]. Current treatments of OS include neo-adjuvant chemotherapy with drugs such as doxorubicin, methotrexate, and cisplatin with the aim of reducing tumour size as well as eradicating micro-metastases
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
